Egyptian International Pharmaceutical Industries Company

CASE:PHAR Stock Report

Market Cap: ج.م6.6b

Egyptian International Pharmaceutical Industries Past Earnings Performance

Past criteria checks 2/6

Egyptian International Pharmaceutical Industries has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 16.4% per year. Egyptian International Pharmaceutical Industries's return on equity is 24.3%, and it has net margins of 16.6%.

Key information

15.6%

Earnings growth rate

4.9%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate16.4%
Return on equity24.3%
Net Margin16.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Egyptian International Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CASE:PHAR Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247,0031,1631,02161
30 Jun 246,3441,09398759
31 Mar 245,7421,23790453
31 Dec 235,23282282743
30 Sep 234,94986980544
30 Jun 234,46386077943
31 Mar 234,02065874342
31 Dec 223,95564371844
30 Sep 223,64858166841
30 Jun 223,62354466043
31 Mar 223,55149461941
31 Dec 213,40948857935
30 Sep 213,17147257332
30 Jun 212,97846154335
31 Mar 212,90146553927
31 Dec 202,88648754821
30 Sep 202,96948853515
30 Jun 203,1135347520
31 Mar 203,2666416520
31 Dec 193,4116715400
30 Sep 193,2947314330
30 Jun 193,126711970
31 Mar 192,999735940
31 Dec 182,816701890
30 Sep 182,784611810
30 Jun 182,767688810
31 Mar 182,654714790
31 Dec 172,527688740
30 Sep 172,372671690
30 Jun 172,210642710
31 Mar 172,079522700
31 Dec 161,969487740
30 Sep 161,873466860
30 Jun 161,793448770
31 Mar 161,745427740
31 Dec 151,697393640
30 Sep 151,682403650
30 Jun 151,646340710
31 Mar 151,624333710
31 Dec 141,578342760
30 Sep 141,528340760
30 Jun 141,453332690
31 Mar 141,397325660
31 Dec 131,357330610

Quality Earnings: PHAR has a high level of non-cash earnings.

Growing Profit Margin: PHAR's current net profit margins (16.6%) are lower than last year (17.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PHAR's earnings have grown by 15.6% per year over the past 5 years.

Accelerating Growth: PHAR's earnings growth over the past year (33.9%) exceeds its 5-year average (15.6% per year).

Earnings vs Industry: PHAR earnings growth over the past year (33.9%) did not outperform the Pharmaceuticals industry 37.9%.


Return on Equity

High ROE: Whilst PHAR's Return on Equity (24.27%) is high, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:58
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Egyptian International Pharmaceutical Industries Company is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aly AdelBeltone Financial
Michel SaidCI Capital Research
Ahmed MoatazEFG-Hermes Research